Ablynx's first inhaled nanobody successfully completes Phase I study
ALX-0171 has the potential to become a first-in-class therapy
21-Sep-2012 -
Ablynx announced that it has achieved positive results from a Phase I study with the first ever inhaled Nanobody, ALX-0171, a trivalent molecule which has been specifically designed by Ablynx for direct lung delivery, via a nebuliser, to treat respiratory syncytial virus (RSV) infections.The ...
Ablynx
phase I studies
respiratory syncytial virus (RSV)